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Haemophilus ducreyi produces an outer membrane protein called DsrA, which is required for serum resis-
tance. An isogenic dsrA mutant, FX517, was constructed previously in H. ducreyi 35000. Compared to its parent,
FX517 cannot survive in normal human serum. When complemented in trans with a plasmid containing dsrA,
FX517 is converted to a serum-resistant phenotype (C. Elkins, K. J. Morrow, Jr., and B. Olsen, Infect. Immun.
68:1608–1619, 2000). To test whether dsrA was transcribed in vivo, we successfully amplified transcripts in five
biopsies obtained from four experimentally infected human subjects. To test whether DsrA was required for
virulence, six volunteers were experimentally infected with 35000 and FX517 and observed for papule and
pustule formation. Each subject was inoculated with two doses (70 to 80 CFU) of live 35000 and 1 dose of
heat-killed bacteria on one arm and with three doses (ranging from 35 to 800 CFU) of live FX517 on the other
arm. Papules developed at similar rates at sites inoculated with the mutant or parent. However, mutant papule
surface areas were significantly smaller than parent papules. The pustule formation rate was 58% (95%
confidence interval [CI] of 28 to 85%) at 12 parent sites, and 0% (95% CI of 0 to 15%) at 18 mutant sites (P 5
0.0004). Although biosafety regulations precluded our testing the complemented mutant in humans, these
results suggest that expression of DsrA facilitates the ability of H. ducreyi to progress to the pustular stage of
disease.
Haemophilus ducreyi causes chancroid, which facilitates
transmission of the human immunodeficiency virus (HIV) (16,
31, 40). Usually, chancroid outbreaks occur sporadically in
industrialized countries (24, 25, 39). Although now rare in the
United States (12), chancroid remains a common public health
problem in many developing countries (9, 10, 13, 26, 30, 37).
Recently, Elkins et al. described a 30-kDa outer membrane
protein called Ducreyi serum resistance A (DsrA) (14). DsrA
is expressed by all naturally occurring strains of H. ducreyi
tested, except for three serum-sensitive strains that were avir-
ulent in animal models (14). The dsrA gene was identified and
sequenced (14), and the predicted amino acid sequence of
DsrA was noted to be similar to the UspA2 protein of Morax-
ella catarrhalis and YadA of Yersinia spp. (14). Both UspA2
and YadA mediate serum resistance (1, 29). An isogenic dsrA
mutant, FX517, of H. ducreyi 35000 was constructed by inser-
tion of a chloramphenicol acetyltransferase (cat) cassette into
the dsrA open reading frame and allele exchange. FX517 no
longer expressed DsrA and was at least 10-fold more serum
susceptible than its parent. FX517 and the three naturally
occurring serum-susceptible strains that lacked DsrA were
complemented in trans with a plasmid containing dsrA, and all
four strains were converted to a serum-resistant phenotype.
The role of DsrA in the pathogenesis of chancroid is cur-
rently unknown. Utilizing a human challenge model, we exam-
ined whether dsrA was transcribed during experimental infec-
tion with H. ducreyi. We also compared the ability of 35000 and
FX517 to cause infection in human volunteers.
MATERIALS AND METHODS
Bacteria. H. ducreyi 35000 and FX517 were described previously (14).
35000HP is a human-passaged variant of 35000 (4, 5, 34).
Detection of dsrA transcripts in vivo. Biopsies of pustules and normal skin
were obtained from five infected and two uninfected volunteers as described in
detail elsewhere (36a). RNA was isolated, and cDNA was synthesized from the
biopsies, from uninfected skin, and from uninfected skin homogenized with 106
CFU of 35000HP using Ultraspec RNA (Biotecx Laboratories, Inc., Houston,
Tex.) and Advantage RT-for-PCR Kit (Clontech Laboratories, Palo Alto, Calif.)
as described elsewhere (36a). RNA that was not subjected to reverse transcrip-
tion (RT) was included to control for DNA contamination. Amplification of
target cDNA was performed with the dsrA-9 and dsrA-11 primers (14) using the
PCR Core Kit Plus (Roche Molecular Biochemicals, Indianapolis, Ind.). PCR-
positive and -negative control templates included genomic DNA from 35000HP
and H2O, respectively. Amplicons were analyzed by electrophoresis of 10 ml of
each PCR reaction on 1.2% agarose gels stained with ethidium bromide.
Human challenge protocol. Healthy adult male and female volunteers over 18
years of age were recruited for the study. Informed consent was obtained from
the subjects for participation and for HIV serology, in accordance with the
human experimentation guidelines of the U.S. Department of Health and Hu-
man Services and the Institutional Review Board of Indiana University–Purdue
University Indianapolis. The experimental challenge protocol, preparation and
inoculation of the bacteria, calculation of the estimated delivered dose (EDD),
and clinical observations were done exactly as described previously (3–5, 34, 35).
When a papule was present, the area of erythema was calculated by measuring
the greatest dimension vertically and horizontally in millimeters and then mul-
tiplying the two measurements. Subjects were observed until they reached a
clinical endpoint, defined as either 14 days after inoculation, development of a
painful pustule, or resolution of infection at all sites. When a clinical endpoint
was achieved, the code was broken and up to two sites with active disease (one
inoculated with the parent and one inoculated with the mutant), if present, were
biopsied with a punch forceps. The subjects were then treated with two doses of
oral ciprofloxacin as described previously.
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Biopsies. Specimens were cut into portions. One portion was fixed in formalin,
and immunohistological studies were done as previously described (28, 34, 35).
One portion was homogenized in 1 ml of freezing medium (3% [wt/vol] tryptic
soy broth, 10% glycerol, 10% heat-inactivated fetal calf serum) for 2 min on ice
and cultured semi-quantitatively as described previously (34, 35).
Phenotypes of recovered bacteria. Individual colonies from the inocula, sur-
face cultures, and biopsies were picked, suspended in freezing medium, and
frozen in 96-well plates. The colonies were scored for susceptibility to chloram-
phenicol on chloramphenicol-containing chocolate agar plates. At least 30 indi-
vidual colonies per specimen, if available, were analyzed. If 30 colonies had the
correct phenotype, then we were confident (95% probability) that, at most, only
11% of the colonies could have the incorrect phenotype in a specimen.
RESULTS
In vivo expression of dsrA. Transcription of dsrA was exam-
ined by RT-PCR of biopsies of five pustules obtained from
four volunteers at sites infected with 35000 or 35000HP. RT-
PCR was also performed on cDNA prepared from uninfected
skin with or without added 35000HP. The expected 385-bp
RT-PCR product was obtained from uninfected skin supple-
mented with bacteria and from the five biopsies of pustules but
not from the uninfected control (Fig. 1 and data not shown).
The sequence of the 385-bp amplicon generated with genomic
DNA from 35000HP was identical to the published sequence
of dsrA. Thus, dsrA was transcribed during experimental infec-
tion of human volunteers.
Human inoculation experiments. Seven healthy adults (four
females, three males; age range of 21 to 46 years; mean age 6
the standard deviation, 33.9 6 8.3 years) volunteered for the
study. Three subjects (158, 159, and 160) were challenged in
the first iteration, and three subjects (155, 165, and 166) were
challenged in the second iteration (Table 1). Subject 161 with-
drew prior to inoculation.
An escalating dose-response study was used to compare the
virulence of the mutant and the parent. We initially inoculated
three subjects at six sites on both arms. One arm was inocu-
lated at three sites with EDDs of 33, 65, and 130 CFU of
FX517. The other arm was inoculated at two sites with EDDs
of 60 CFU of the parent strain and at a third site with 130 CFU
of heat-killed FX517. Papules developed at five of six sites
inoculated with the parent strain and at seven of nine sites
inoculated with the mutant. All mutant papules resolved (Ta-
ble 1). Pustules developed at three of six sites inoculated with
the parent strain and at none of the nine sites inoculated with
the mutant.
Since the mutant was impaired in its ability to cause pus-
tules, we infected three more subjects and increased the dose
of the mutant. For this group of subjects, three sites were
inoculated with EDDs of 213, 427, and 855 CFU of FX517.
Two sites were inoculated with 93 CFU of the parent strain,
and a third site was inoculated with 855 CFU of heat-killed
FX517. Six of six parent sites and five of nine mutant sites
developed papules (Table 1). At the clinical endpoint, two
parent papules and all five mutant papules resolved. Pustules
developed at four of six parent sites and at none of nine mutant
sites. Thus, FX517 was impaired in its ability to form pustules
even at doses tenfold that of the parent strain.
The cumulative results for the two iterations showed that
papules developed at 92% (exact binomial 95% confidence
interval [CI], 61 to 99%) of sites inoculated with 35000 and at
67% (exact binomial 95% CI, 41 to 87%) of sites inoculated
with FX517 (one-tailed Fisher’s exact test, P 5 0.125). During
the trial, we noted that papules on one arm appeared smaller
than papules on the other arm. We calculated the surface area
of papule erythema at each site 24 and 48 h after inoculation
after the code was broken. The surface areas of mutant papules
were significantly smaller than the parent papules at both time
points (Table 2). The surface areas of the mutant papules were
statistically similar to those of the heat-killed control (Table 2).
Thus, the mutant caused smaller lesions than the parent during
the initial stages of infection.
Overall, pustules formed at 7 of 12 (58%; exact binomial
95% CI, 28 to 85%) sites inoculated with 35000 compared to 0
of 18 (0%; exact binomial 95% CI, 0 to 15%) sites inoculated
with FX517 (one-tailed Fisher’s exact test, P 5 0.0004). Thus,
FIG. 1. Composite agarose gel stained with ethidium bromide from
PCR and RT-PCR products obtained using dsrA primers. Lanes 1 and
2 contain 35000HP genomic DNA and no template, respectively.
cDNA (lanes 3, 5, 7, and 9) and RNA that was not reverse transcribed
(lanes 4, 6, 8, and 10) were prepared from uninfected skin (lanes 3 and
4), uninfected skin homogenized with H. ducreyi (lanes 5 and 6), a
biopsy from volunteer 160 (lanes 7 and 8), and a biopsy from volunteer
142 (lanes 9 and 10).


































a Each volunteer was inoculated at two sites with parent strain 35000 and at
three sites with mutant strain FX517. Volunteers 158, 159, and 160 were inoc-
ulated in the first iteration, and volunteers 155, 165, and 166 were inoculated in
the second iteration.
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the mutant was impaired in its ability to form pustules when
compared to the parent.
Bacterial recovery and cellular infiltrate from mutant and
parent lesions. From daily surface cultures, H. ducreyi was
recovered intermittently from 1 of 12 parent sites, while no
bacteria were recovered from the 18 mutant sites or the 6
heat-killed sites. Four subjects had parent sites that contained
pustules at endpoint and were biopsied. H. ducreyi were recov-
ered (range, 2.6 3 104 to 4.1 3 106 CFU per g of tissue) from
four of four parent biopsies. We also examined the cellular
infiltrate in two parent biopsies. Micropustules with polymor-
phonuclear leukocytes were present in the epidermis (data not
shown). The dermis contained a perivascular infiltrate of
mononuclear cells and some polymorphonuclear leukocytes,
and the venules were lined with reactive endothelial cells. The
mononuclear cells stained positively with a CD3 marker veri-
fying their T-cell origin (data not shown). No disease was
present at the mutant sites at endpoint, and no mutant sites
were biopsied in accordance with our protocols.
Confirmation of the antibiotic susceptibility of the recovered
bacteria. To confirm that the inocula were correct and that no
cross-contamination of sites had occurred during infection,
individual colonies from each of the broth cultures used to
prepare the inocula, from surface cultures, and from biopsy
specimens were analyzed for chloramphenicol susceptibility
(Cms). For the two parent and two mutant broth cultures used
to prepare the inocula, all 88 parent colonies and 88 mutant
colonies tested were phenotypically correct (mutant, Cmr; par-
ent, Cms). All 40 colonies obtained from surface cultures of
parent sites were phenotypically correct (Cms). A total of 192
parent colonies obtained from biopsies were phenotypically
correct (Cms). Thus, all colonies tested from the inocula, sur-
face cultures, and biopsies had the expected antibiotic suscep-
tibility.
DISCUSSION
In this study, we amplified dsrA cDNA from RNA of pus-
tules of experimentally infected subjects, suggesting that DsrA
was expressed in vivo. We also tested the ability of an isogenic
DsrA-deficient mutant (FX517) to infect human volunteers. In
our volunteer group, the mutant formed papules at a rate
similar to that of the parent strain, but mutant papules were
significantly smaller and did not progress to the pustular stage
of disease. In previous studies, isogenic hgbA receptor and pal
mutants were impaired in their ability to form pustules in
humans (3, 17). This is the third demonstration that a putative
virulence factor of H. ducreyi facilitates pustule formation in
humans.
Our institutional biosafety committee does not permit the
testing of mutants complemented with plasmids in human sub-
jects. We cannot exclude the possibility that the decreased
virulence of FX517 was due to a secondary mutation or a polar
effect of the cat cassette. However, complementation of FX517
in trans restores expression of DsrA and serum resistance to
the mutant (14). Thus, it is highly likely that the decreased
virulence of FX517 was due to the mutation of dsrA.
The bactericidal activity of human serum is an important
component of innate host defenses, and many bacterial patho-
gens are serum resistant. H. ducreyi 35000 is resistant to normal
human serum at concentrations of up to 50% (18). Although
initial investigations by Odumeru and colleagues suggested
that truncations in the lipooligosaccharide of H. ducreyi medi-
ated serum sensitivity (27), recent studies showed that the loss
of serum resistance was due to the loss of DsrA and not to
truncations in lipooligosaccharide (14, 18, 36). In natural in-
fection, H. ducreyi is thought to gain access to the skin via
wounds that occur during intercourse (25). Puncture wounds
are required to initiate experimental infection (35). FX517
may have been less efficient at establishing and maintaining
infection in our volunteers because it was killed by serum that
leaks into the skin during wound healing and inflammation
(20).
DsrA is a member of a growing family of proteins that share
homology at their C termini and confer serum resistance
and/or the ability to adhere to human cells on their respective
organisms (1, 2, 14, 21, 23, 29, 32, 33). This family includes the
YadA protein of Yersinia spp., the UspA2 protein of M. ca-
tarrhalis and the Eib protein of certain Escherichia coli strains.
Each protein appears to have a unique mechanism of diverting
complement-mediated antibody killing. For example, YadA
binds complement factor H (29), UspA2 binds the complement
regulatory protein vitronectin (23), and the Eib proteins bind
immunoglobulins via the Fc portion of the molecule (32, 33).
The mechanism by which DsrA mediates serum resistance is
not known and is currently under investigation.
Attachment of bacteria to host cells is a critical step in the
establishment of infection. H. ducreyi attaches to human ker-
atinocytes and fibroblasts in vitro (6, 11, 19, 22, 38). Elkins and
colleagues tested the ability of FX517 to attach to a keratino-
cyte cell line and found that FX517 adhered significantly less
efficiently than the parent strain (L. E. Cole, C. Elkins, T.
Kawula, Abstr. 100th Gen. Meet. Am. Soc. Microbiol., abstr.
B-122, p. 69, 2000). The complemented mutant regained its
ability to attach. However, confocal microscopy data failed to
show that H. ducreyi binds to keratinocytes throughout the
course of experimental infection of human subjects (8; unpub-
lished observations). Thus, the significance of the in vitro ob-
servations and their relevance to human disease is not clear.
Throughout the course of experimental infection, H. ducreyi
colocalizes with collagen in the upper dermis (unpublished
observations). H. ducreyi binds to collagen in vitro (7). YadA
mediates binding to collagen through repeated NSVAIG-S
motifs in the amino-terminal half of the protein (15). DsrA
lacks sequences homologous to the N-terminal half of YadA,
and it is unlikely that DsrA mediates collagen binding through
a similar motif.
In summary, our data show that dsrA is transcribed in vivo
and suggests that expression of DsrA is required for the viru-
lence of H. ducreyi. The homology among DsrA, YadA,
TABLE 2. Papule surface areaa
Day
Mean papule surface area
(mm2) 6 SD P
H M P M versus H M versus P
1 5.17 6 4.45 5.11 6 6.21 37.7 6 37.7 1 0.0009
2 2.00 6 3.49 2.06 6 4.32 39.9 6 35.2 0.998 0.0001
a H, heat-killed control; M, mutant (FX517); P, parent (35000).
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UspA2, and the Eib proteins suggests that DsrA may have
multiple functions, including serum resistance and cell adher-
ence. Therefore, FX517 may have been attenuated in experi-
mental infection for multiple reasons. Future studies will focus
on delineating the mechanisms by which DsrA mediates serum
resistance and its possible role in adherence.
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